← Patent-cliff monitor small molecule ALUNBRIG BRIGATINIB
Loss of exclusivity November 2035 latest FDA-listed patent expiry
Company TAKEDA PHARMACEUTICALS USA INC
Drug detail Brand name ALUNBRIG Active ingredient BRIGATINIB Strength 180MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval October 2017 Marketing status RX
Listed patents Patent Expires Type 10385078 November 2035 substance, product 9611283 April 2034 use U-2837 9012462 April 2031 substance 9273077 May 2029 use U-2837
Regulatory exclusivity Code Expires ODE-300 May 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.